Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years-Reference-Cited by-同舟云学术

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:4159-4161
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Ghia Paolo¹,Owen Carolyn²,Barrientos Jacqueline C.³,Barr Paul M.⁴,Mato Anthony R.⁵,Shi Chunxue⁶,Szoke Anita⁷,Abbazio Chris⁷,Krigsfeld Gabriel S.⁷,Burger Jan A.⁸

Affiliation:

1. 1Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

2. 2Tom Baker Cancer Centre, University of Calgary and Alberta Health Services, Calgary, Canada

3. 3Columbia University Division of Hematology/Oncology, Mount Sinai Medical Center, Miami, FL

4. 4Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

5. 5Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY

6. 6Everest Clinical Research, Owings Mills, MD

7. 7Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA

8. 8Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy;Current Medical Research and Opinion;2024-07

3. Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints;Expert Review of Hematology;2024-06-13

4. Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population;Cancers;2024-03-07

5. Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study;European Journal of Haematology;2024-02-11